Fresnais

In the frame of a clinical study aiming at evaluating the pharmacokinetics of a new therapeutic monoclonal antibody (mAb), you need to develop the adapted analytical strategy to quantify the new mAb in plasma samples with selectivity and sensitivity.

Which analytical strategy do you think would be the most suitable for the mAb quantification in plasma:

For the quantification of a new monoclonal antibody (mAb) in human plasma, you need to find the right surrogate peptide to monitor in order to obtain a sensitive and specific quantification. Which one of the following observations should justify the rejection of a peptide as potential surrogate peptide:

You want to quantify a small molecule drug using on-surface MS analysis from blood

self-collected at home by patients living in several European countries. Which analytical

combination (blood collection/analytical method) do you then need to use:

You need to quantify a small molecule drug from tissue slices deposited on normal glass slides. You want to add a separative step during your process to improve the sensitivity and specificity of your method. Which analytical combination (sample preparation/analytical method) would you then need to use:

What is not tested in bioanalytical method validation:

Rapidly quantifying small molecular drug in blood samples collected from patients (Sample- Preparation-Method):